December 23, 2020 -- The European Commission (EC) has granted a conditional marketing authorization to Pfizer and BioNTech for their COVID-19 vaccine.
The vaccine is authorized for use in the European Union (EU) to prevent COVID-19 in individuals 16 years of age and older. The messenger RNA-based vaccine, which received an emergency use authorization in the U.S. in mid-December, is administered in two doses given three weeks apart.
The companies said they can immediately ship initial doses to the 27 member states of the EU. The EC had already entered into an agreement to receive 200 million doses of the vaccine, with an option to buy an additional 100 million doses in 2021.